Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | (21189378) | ||||||||||||
Authors | Klümpen HJ, Queiroz KC, Spek CA, van Noesel CJ, Brink HC, de Leng WW, de Wilde RF, Mathus-Vliegen EM, Offerhaus GJ, Alleman MA, Westermann AM, Richel DJ | ||||||||||||
Title | mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. | ||||||||||||
|
|||||||||||||
URL | |||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|---|---|---|---|---|
STK11 | D194E | missense | unknown | STK11 D194E lies within the protein kinase domain of the Stk11 protein (UniProt.org). D194E has been identified in the scientific literature (PMID: 21189378, PMID: 37179440), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Feb 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
STK11 D194E STK11 loss | pancreatic cancer | predicted - sensitive | Everolimus | Case Reports/Case Series | Actionable | In a clinical case study, a pancreatic cancer patient with Peutz-Jeghers syndrome harboring STK11 D194E and loss of heterozygosity of the other STK11 allele in the tumor achieved a partial response following treatment with Afinitor (everolimus), but progressed after 9 months (PMID: 21189378). | 21189378 |